An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
Health Canada has approved a second generic version of Ozempic, and this one is made by a Canadian company. In plain terms, another company is now allowed to sell a cheaper copy of the drug that does the same job as the brand-name version, under Canadian regulatory approval. Ozempic is the brand name for the drug semaglutide. Semaglutide is a type of medicine that acts like a natural hormone your gut makes after you eat. That hormone helps control appetite and blood sugar by telling your brain you’re full and by slowing how quickly food leaves your stomach. Ozempic is most commonly used to treat type 2 diabetes, and a similar dose, sold as Wegovy, is used for weight management. The approval itself is a regulatory decision, not a new clinical study. Health Canada reviewed data from the Canadian company and decided the generic is equivalent enough to the original that it can be sold as the same medicine. Generics must show they contain the same active ingredient and work in the same way; they do not usually require new trials in large groups of people. The announcement doesn’t change how effective Ozempic/semaglutide is — it just means another manufacturer can make and sell it in Canada. Why this matters is mostly about access and cost. Branded drugs like Ozempic can be expensive, and generics tend to be cheaper once they hit the market. More competition can lower prices and make it easier for people who need semaglutide for diabetes care to get it without breaking the bank. It could also ease shortages or supply problems, since more manufacturers mean more available supply. There are still important caveats. A generic is equivalent on the active ingredient, but packaging, delivery devices (like pens), and instructions might differ, so patients should check with their pharmacist and doctor before switching. Side effects and risks of semaglutide don’t change because a generic is approved; people with a history of certain conditions (for example, some rare thyroid cancers or pancreatitis) should follow medical guidance. Also, regulatory approval in Canada doesn’t necessarily mean the same product is approved elsewhere. Bottom line: Canada will soon have a second, locally made generic version of Ozempic, which could help lower costs and improve access for people who need semaglutide for diabetes care.
Source: CBC